U.S., June 7 -- ClinicalTrials.gov registry received information related to the study (NCT07008469) titled 'Global Open-Label Extension Study of Del-desiran for the Treatment of DM1' on May 29.
Brief Summary: A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous Delpacibart Etedesiran (abbreviated del-desiran, formerly AOC 1001) for the Treatment of Myotonic Dystrophy Type 1
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Myotonic Dystrophy Type 1
DM1
Myotonic Dystrophy
Myotonia
Myotonic Dystrophy 1
Myotonic Disorders
Steinert Myotonic Dystrophy
Steinert's Disease
Intervention:
DRUG: Del-desiran (AOC 1001)
Del-desiran will be administered by intra...